ASPHF's Quick Ratio is ranked worse than 68.88% of 1417
companies
in the Biotechnology industry
Industry Median: 3.6
vs ASPHF: 1.77
Ascentage Pharma Group International (OTCPK:ASPHF) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Ascentage Pharma Group International Quick Ratio Related Terms
Ascentage Pharma Group International Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascentage Pharma Group International Quick Ratio Chart
For the Biotechnology subindustry, Ascentage Pharma Group International's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascentage Pharma Group International Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Ascentage Pharma Group International's Quick Ratio falls into.
Ascentage Pharma Group International Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascentage Pharma Group International (ASPHF) has a Quick Ratio of 1.77 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Ascentage Pharma Group International and its competitors. This is 58% below median its historical median of 4.21. Over the past decade, Ascentage Pharma Group International's Quick Ratio has ranged from 1.26 to 9.41. According to the industry distribution chart, Ascentage Pharma Group International ranks #976 out of 1417 companies in the Biotechnology industry, placing it in the top 68.9%.
Is Ascentage Pharma Group International's Quick Ratio too high?
Ascentage Pharma Group International's current Quick Ratio of 1.77 is 58% below median its 10-year median of 4.21. Over the past 10 years, this metric has ranged from a low of 1.26 to a high of 9.41. The Biotechnology industry median Quick Ratio is 3.60. Ascentage Pharma Group International's value of 1.77 is 50.8% below this industry median. Based on the distribution chart, Ascentage Pharma Group International ranks #976 out of 1417 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ascentage Pharma Group International has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ascentage Pharma Group International's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascentage Pharma Group International ranks #976 out of 1417 companies for Quick Ratio. This places Ascentage Pharma Group International in the lower half of its industry. The industry median Quick Ratio is 3.60. Ascentage Pharma Group International's value of 1.77 is 50.8% below this benchmark. Historically, Ascentage Pharma Group International's own Quick Ratio has ranged from 1.26 to 9.41 over the past decade. While the company's 10-year median is 4.21 vs. the industry median of 3.60, Ascentage Pharma Group International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascentage Pharma Group International's current Quick Ratio of 1.77 is 50.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Ascentage Pharma Group International and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascentage Pharma Group International's current Quick Ratio is 1.77, which is 58% below median its own 10-year median of 4.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascentage Pharma Group International stock overvalued right now?
Based on GuruFocus' analysis, Ascentage Pharma Group International (ASPHF) is currently considered Possible Value Trap. The stock's GF Value™ is $6.61, compared to a current price of $4.53 — trading 31.5% below its estimated fair value. The current Quick Ratio is 1.77, which is 58% below median its 10-year median of 4.21 and 50.8% below the Biotechnology industry median of 3.60. Ascentage Pharma Group International's overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Ascentage Pharma Group International (ASPHF), the current Quick Ratio is 1.77 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascentage Pharma Group International (ASPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Ascentage Pharma Group International stock appears to be undervalued.
The current stock price of $4.53 is trading 31.5% below its estimated GF Value™ of $6.61.
GuruFocus considers Ascentage Pharma Group International to be Possible Value Trap.
Key valuation signals for ASPHF:
Quick Ratio: 1.77 (58% below median its 10-year median of 4.21)
GF Value™: $6.61 vs. price of $4.53 (31.5% below fair value)
Industry Position: 50.8% below the Biotechnology median (#976 of 1417)
No single metric tells the full story. See the ASPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascentage Pharma Group International Business Description
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
71GF Score
Get the complete analysis for ASPHF
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASPHF has been successfully added to your 
